12 results on '"Bijker, Nina"'
Search Results
2. Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: first results of the EORTC randomised phase III trial 10853. EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group.
- Author
-
Julien, Jean-Pierre, Bijker, Nina, Fentiman, Ian S., Peterse, Johannes L., Delledonne, Vincenzo, Rouanet, Philippe, Avril, Antoine, Sylvester, Richard, Mignolet, Francoise, Bartelink, Harry, Van Dongen, Joop A., Julien, J P, Bijker, N, Fentiman, I S, Peterse, J L, Delledonne, V, Rouanet, P, Avril, A, Sylvester, R, and Mignolet, F
- Subjects
- *
BREAST cancer , *ELECTROTHERAPEUTICS , *MEDICAL radiology , *PHYSIOLOGICAL therapeutics , *RADIOTHERAPY - Abstract
Background: Ductal carcinoma in situ (DCIS) of the breast is a disorder that has become more common since it may manifest as microcalcifications that can be detected by screening mammography. Since selected women with invasive cancer can be treated safely with breast conservation therapy it is paradoxical that total mastectomy has remained the standard treatment for DCIS. We did a randomised phase III clinical trial to investigate the role of radiotherapy after complete local excision of DCIS.Methods: Between 1986 and 1996, women with clinically or mammographically detected DCIS measuring less than or equal to 5 cm were treated by complete local excision of the lesion and then randomly assigned to either no further treatment (n=503) or to radiotherapy (n=507; 50 Gy in 5 weeks to the whole breast). The median duration of follow-up was 4.25 years (maximum 12.0 years). All analyses were by intention to treat.Findings: 500 patients were followed up in the no further treatment group and 502 in the radiotherapy group. In the no further treatment group 83 women had local recurrence (44 recurrences of DCIS, and 40 invasive breast cancer). In the radiotherapy group 53 women had local recurrences (29 recurrences of DCIS, and 24 invasive breast cancer). The 4-year local relapse-free was 84% in the group treated with local excision alone compared with 91% in the women treated by local excision plus radiotherapy (log rank p=0.005; hazard ratio 0.62). Similar reductions in the risk of invasive (40%, p=0.04) and non-invasive (35%, p=0.06) local recurrence were seen.Conclusions: Radiotherapy after local excision for DCIS, as compared with local excision alone, reduced the overall number of both invasive and non-invasive recurrences in the ipsilateral breast at a median follow-up of 4.25 years. [ABSTRACT FROM AUTHOR]- Published
- 2000
- Full Text
- View/download PDF
3. 388: CBCT-guided online adaptive radiotherapy in breast cancer patients – a prospective trial NL2021.0624.
- Author
-
van Vlaenderen, Angelique R.W., Nelissen, Koen J., Rijn, Judith G. Middelburg-van, Rijksen, Barbara L.T., Visser, Jorrit, Admiraal, Marjan, Goudschaal, Karin N., Bucko, Ewa, Glebbeek, Cassey E., Bijker, Nina, Slotman, Ben, Verbakel, Wilko F.A.R., and van den Bongard, Desiree H.J.G.
- Subjects
- *
BREAST cancer , *CANCER patients , *CANCER radiotherapy - Published
- 2024
- Full Text
- View/download PDF
4. Prediction of pathologic complete response after single-dose MR-guided partial breast irradiation in low-risk breast cancer patients: the ABLATIVE-2 trial—a study protocol.
- Author
-
Civil, Yasmin A., Oei, Arlene L., Duvivier, Katya M., Bijker, Nina, Meijnen, Philip, Donkers, Lorraine, Verheijen, Sonja, van Kesteren, Zdenko, Palacios, Miguel A., Schijf, Laura J., Barbé, Ellis, Konings, Inge R. H. M., -van der Houven van Oordt, C. Willemien Menke, Westhoff, Paulien G., Meijer, Hanneke J. M., Diepenhorst, Gwen M. P., Thijssen, Victor, Mouliere, Florent, Slotman, Berend J., and van der Velde, Susanne
- Subjects
- *
ACCELERATED partial breast irradiation , *LOBULAR carcinoma , *BREAST cancer , *CANCER patients , *TUMOR classification , *LUMPECTOMY , *SENTINEL lymph nodes , *PATHOLOGIC complete response - Abstract
Background: Partial breast irradiation (PBI) is standard of care in low-risk breast cancer patients after breast-conserving surgery (BCS). Pre-operative PBI can result in tumor downstaging and more precise target definition possibly resulting in less treatment-related toxicity. This study aims to assess the pathologic complete response (pCR) rate one year after MR-guided single-dose pre-operative PBI in low-risk breast cancer patients. Methods: The ABLATIVE-2 trial is a multicenter prospective single-arm trial using single-dose ablative PBI in low-risk breast cancer patients. Patients ≥ 50 years with non-lobular invasive breast cancer ≤ 2 cm, grade 1 or 2, estrogen receptor-positive, HER2-negative, and tumor-negative sentinel node procedure are eligible. A total of 100 patients will be enrolled. PBI treatment planning will be performed using a radiotherapy planning CT and -MRI in treatment position. The treatment delivery will take place on a conventional or MR-guided linear accelerator. The prescribed radiotherapy dose is a single dose of 20 Gy to the tumor, and 15 Gy to the 2 cm of breast tissue surrounding the tumor. Follow-up MRIs, scheduled at baseline, 2 weeks, 3, 6, 9, and 12 months after PBI, are combined with liquid biopsies to identify biomarkers for pCR prediction. BCS will be performed 12 months after radiotherapy or after 6 months, if MRI does not show a radiologic complete response. The primary endpoint is the pCR rate after PBI. Secondary endpoints are radiologic response, toxicity, quality of life, cosmetic outcome, patient distress, oncological outcomes, and the evaluation of biomarkers in liquid biopsies and tumor tissue. Patients will be followed up to 10 years after radiation therapy. Discussion: This trial will investigate the pathological tumor response after pre-operative single-dose PBI after 12 months in patients with low-risk breast cancer. In comparison with previous trial outcomes, a longer interval between PBI and BCS of 12 months is expected to increase the pCR rate of 42% after 6–8 months. In addition, response monitoring using MRI and biomarkers will help to predict pCR. Accurate pCR prediction will allow omission of surgery in future patients. Trial registration: The trial was registered prospectively on April 28th 2022 at clinicaltrials.gov (NCT05350722). [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
5. Optimal Patient Positioning (Prone Versus Supine) for VMAT in Gynecologic Cancer: A Dosimetric Study on the Effect of Different Margins.
- Author
-
Heijkoop, Sabrina T., Westerveld, Henrike, Bijker, Nina, Feije, Raphael, Sharfo, Abdul W., van Wieringen, Niek, Mens, Jan Willem M., Stalpers, Lukas J.A., and Hoogeman, Mischa S.
- Subjects
- *
GYNECOLOGIC cancer , *CANCER treatment , *ORGANS (Anatomy) , *RADIOTHERAPY , *PATIENTS , *HUMAN body , *COMPARATIVE studies , *FEMALE reproductive organ tumors , *LYING down position , *RESEARCH methodology , *MEDICAL cooperation , *COMPUTERS in medicine , *PATIENT positioning , *RADIATION doses , *RADIATION measurements , *RESEARCH , *SUPINE position , *THERAPEUTICS , *EVALUATION research , *TREATMENT effectiveness - Abstract
Purpose/objective: It is unknown whether the historically found dosimetric advantages of treating gynecologic cancer with the patient in a prone position with use of a small-bowel displacement device (belly-board) remain when volumetric arc therapy (VMAT) is used and whether these advantages depend on the necessary margin between clinical target volume (CTV) and planning target volume (PTV). The aim of this study is to determine the best patient position (prone or supine) in terms of sparing organs at risk (OAR) for various CTV-to-PTV margins and VMAT dose delivery.Methods and Materials: In an institutional review board-approved study, 26 patients with gynecologic cancer scheduled for primary (9) or postoperative (17) radiation therapy were scanned in a prone position on a belly-board and in a supine position on the same day. The primary tumor CTV, nodal CTV, bladder, bowel, and rectum were delineated on both scans. The PTVs were created each with a different margin for the primary tumor and nodal CTV. The VMAT plans were generated with our in-house system for automated treatment planning. For all margin combinations, the supine and prone plans were compared with consideration of all OAR dose-volume parameters but with highest priority given to bowel cavity V45Gy (cm(3)).Results: For both groups, the prone position reduced the bowel cavity V45Gy, in particular for nodal margins ≥10 mm (ΔV45Gy = 23.9 ± 10.6 cm(3)). However, for smaller margins, the advantage was much less pronounced (ΔV45Gy = 6.5 ± 3.0 cm(3)) and did not reach statistical significance. The rectum mean dose (Dmean) was significantly lower (ΔDmean = 2.5 ± 0.3 Gy) in the prone position for both patient groups and for all margins, and the bladder Dmean was significantly lower in the supine position (ΔDmean = 2.6 ± 0.4 Gy) only for the postoperative group. The advantage of the prone position was not present if it needed a larger margin than the supine position.Conclusion: For patients with gynecologic cancer, the historically found dosimetric advantages for the prone position remain for modern dose delivery techniques if large margins are needed. However, the advantage is lost for small margins and if the prone position needs a larger margin than the supine position. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
6. Transparency in quality of radiotherapy for breast cancer in the Netherlands: a national registration of radiotherapy-parameters.
- Author
-
Maliko, Nansi, Stam, Marcel R., Boersma, Liesbeth J., Vrancken Peeters, Marie-Jeanne T. F. D., Wouters, Michel W. J. M., KleinJan, Eline, Mulder, Maurice, Essers, Marion, Hurkmans, Coen W., and Bijker, Nina
- Subjects
- *
BREAST cancer , *MEDICAL communication , *ACCELERATED partial breast irradiation , *CANCER radiotherapy , *DIGITAL communications , *RECORDING & registration - Abstract
Background: Radiotherapy (RT) is part of the curative treatment of approximately 70% of breast cancer (BC) patients. Wide practice variation has been reported in RT dose, fractionation and its treatment planning for BC. To decrease this practice variation, it is essential to first gain insight into the current variation in RT treatment between institutes. This paper describes the development of the NABON Breast Cancer Audit-Radiotherapy (NBCA-R), a structural nationwide registry of BC RT data of all BC patients treated with at least surgery and RT.Methods: A working group consisting of representatives of the BC Platform of the Dutch Radiotherapy Society selected a set of dose volume parameters deemed to be surrogate outcome parameters, both for tumour control and toxicity. Two pilot studies were carried out in six RT institutes. In the first pilot study, data were manually entered into a secured web-based system. In the second pilot study, an automatic Digital Imaging and Communications in Medicine (DICOM) RT upload module was created and tested.Results: The NBCA-R dataset was created by selecting RT parameters describing given dose, target volumes, coverage and homogeneity, and dose to organs at risk (OAR). Entering the data was made mandatory for all Dutch RT departments. In the first pilot study (N = 1093), quite some variation was already detected. Application of partial breast irradiation varied from 0 to 17% between the 6 institutes and boost to the tumour bed from 26.5 to 70.2%. For patients treated to the left breast or chest wall only, the average mean heart dose (MHD) varied from 0.80 to 1.82 Gy; for patients treated to the breast/chest wall only, the average mean lung dose (MLD) varied from 2.06 to 3.3 Gy. In the second pilot study 6 departments implemented the DICOM-RT upload module in daily practice. Anonymised data will be available for researchers via a FAIR (Findable, Accessible, Interoperable, Reusable) framework.Conclusions: We have developed a set of RT parameters and implemented registration for all Dutch BC patients. With the use of an automated upload module registration burden will be minimized. Based on the data in the NBCA-R analyses of the practice variation will be done, with the ultimate aim to improve quality of BC RT. Trial registration Retrospectively registered. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
7. Sexual Functioning and Relationship Satisfaction of Partners of Breast Cancer Survivors Who Receive Internet-Based Sex Therapy.
- Author
-
Hummel, Susanna B., van Lankveld, Jacques J.D.M., Oldenburg, Hester S.A., Hahn, Daniela E.E., Kieffer, Jacobien M., Gerritsma, Miranda A., Kuenen, Marianne A., Bijker, Nina, Borgstein, Paul J., Heuff, Gijsbert, Lopes Cardozo, Alexander M.F., Plaisier, Peter W., Rijna, Herman, van der Meij, Suzan, van Dulken, Eric J., Vrouenraets, Bart C., Broomans, Eva, and Aaronson, Neil K.
- Subjects
- *
SEX therapy , *SEXUAL excitement , *BREAST cancer , *CANCER patients , *BEHAVIOR therapy - Abstract
As part of a larger, randomized controlled trial, we evaluated longitudinally the sexual functioning and relationship satisfaction of 69 partners of breast cancer (BC) survivors who received Internet-based cognitive behavioral therapy (CBT) for sexual dysfunction. The findings suggest that Internet-based CBT positively affects the partners' immediate post-CBT and longer-term overall sexual satisfaction, sexual intimacy, and sexual relationship satisfaction. No sustained changes in other areas of sexual functioning were observed. Our CBT program was focused primarily on the sexual health of the BC survivors. We recommend that future programs include more psychoeducational and behavioral elements targeted at the partners. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
8. Active surveillance versus treatment in low-risk DCIS: Women's preferences in the LORD-trial.
- Author
-
Schmitz, Renée S.J.M., Engelhardt, Ellen G., Gerritsma, Miranda A., Sondermeijer, Carine M.T., Verschuur, Ellen, Houtzager, Julia, Griffioen, Rosalie, Retèl, Valesca, Bijker, Nina, Mann, Ritse M., van Duijnhoven, Frederieke, Wesseling, Jelle, and Bleiker, Eveline M.A.
- Subjects
- *
BREAST cancer treatment , *PUBLIC health surveillance , *CONFIDENCE intervals , *MULTIVARIATE analysis , *DUCTAL carcinoma , *BREAST cancer , *PATIENTS' attitudes , *PSYCHOLOGY of women , *QUESTIONNAIRES , *DECISION making , *DESCRIPTIVE statistics , *THEMATIC analysis , *LOGISTIC regression analysis , *ODDS ratio , *EDUCATIONAL attainment - Abstract
Ductal carcinoma in situ (DCIS) can progress to invasive breast cancer (IBC), but most DCIS lesions remain indolent. However, guidelines recommend surgery, often supplemented by radiotherapy. This implies overtreatment of indolent DCIS. The non-randomised patient preference LORD-trial tests whether active surveillance (AS) for low-risk DCIS is safe, by giving women with low-risk DCIS a choice between AS and conventional treatment (CT). Here, we aim to describe how participants are distributed among both trial arms, identify their motives for their preference, and assess factors associated with their choice. Data were extracted from baseline questionnaires. Descriptive statistics were used to assess the distribution and characteristics of participants; thematic analyses to extract self-reported reasons for the choice of trial arm, and multivariable logistic regression analyses to investigate associations between patient characteristics and chosen trial arm. Of 377 women included, 76% chose AS and 24% CT. Most frequently cited reasons for AS were "treatment is not (yet) necessary" (59%) and trust in the AS-plan (39%). Reasons for CT were cancer worry (51%) and perceived certainty (29%). Women opting for AS more often had lower educational levels (OR 0.45; 95% confidence interval [CI], 0.22–0.93) and more often reported experiencing shared decision making (OR 2.71; 95% CI, 1.37–5.37) than women choosing CT. The LORD-trial is the first to offer women with low-risk DCIS a choice between CT and AS. Most women opted for AS and reported high levels of trust in the safety of AS. Their preferences highlight the necessity to establish the safety of AS for low-risk DCIS. • The LORD-trial investigates whether active surveillance is safe in low-risk DCIS. • Women strongly preferred active surveillance (76%) to conventional treatment (24%). • Most cited reason for active surveillance was "treatment is not (yet) necessary". • Most cited reason for conventional treatment was "avoiding cancer worry". [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
9. Internet-Based Cognitive Behavioral Therapy Realizes Long-Term Improvement in the Sexual Functioning and Body Image of Breast Cancer Survivors.
- Author
-
Hummel, Susanna B., van Lankveld, Jacques J. D. M., Oldenburg, Hester S. A., Hahn, Daniela E. E., Kieffer, Jacobien M., Gerritsma, Miranda A., Kuenen, Marianne A., Bijker, Nina, Borgstein, Paul J., Heuff, Gijsbert, Cardozo, Alexander M. F. Lopes, Plaisier, Peter W., Rijna, Herman, van der Meij, Suzan, van Dulken, Eric J., Vrouenraets, Bart C., Broomans, Eva, and Aaronson, Neil K.
- Subjects
- *
COGNITIVE therapy , *SEXUAL dysfunction , *BODY image , *LUST , *SEXUAL excitement , *BREAST cancer patients - Abstract
The study aim was to evaluate the long-term efficacy of Internet-based cognitive behavioral therapy (CBT) for sexual dysfunctions in 84 breast cancer survivors. The positive effects of the intervention on overall sexual functioning, sexual desire, sexual arousal, vaginal lubrication, discomfort during sex, sexual distress, and body image observed immediately posttreatment were maintained at three- and nine-month follow-ups. Although sexual pleasure decreased during follow-up, it did not return to baseline levels. Our findings provide evidence that Internet-based CBT has a sustained, positive effect on sexual functioning and body image of breast cancer survivors with a sexual dysfunction. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
10. Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ – The LORD study.
- Author
-
Elshof, Lotte E., Tryfonidis, Konstantinos, Slaets, Leen, van Leeuwen-Stok, A. Elise, Skinner, Victoria P., Dif, Nicolas, Pijnappel, Ruud M., Bijker, Nina, Rutgers, Emiel J.Th., and Wesseling, Jelle
- Subjects
- *
BREAST cancer , *HORMONE therapy , *LONGITUDINAL method , *MEDICAL cooperation , *PUBLIC health surveillance , *RADIOTHERAPY , *RESEARCH , *SAFETY , *RANDOMIZED controlled trials , *CARCINOMA in situ , *DUCTAL carcinoma - Abstract
Background The current debate on overdiagnosis and overtreatment of screen-detected ductal carcinoma in situ (DCIS) urges the need for prospective studies to address this issue. A substantial number of DCIS lesions will never form a health hazard, particularly if it concerns non- to slow-growing low-grade DCIS. The LORD study aims to evaluate the safety of active surveillance in women with low-risk DCIS. Design This is a randomised, international multicentre, open-label, phase III non-inferiority trial, led by the Dutch Breast Cancer Research Group (BOOG 2014-04) and the European Organization for Research and Treatment of Cancer (EORTC-BCG 1401). Standard treatment will be compared to active surveillance in 1240 women aged ⩾45 years with asymptomatic, screen-detected, pure low-grade DCIS based on vacuum-assisted biopsies of microcalcifications only. Both study arms will be monitored with annual digital mammography for a period of 10 years. The primary end-point is 10-year ipsilateral invasive breast cancer free percentage. Secondary end-points include patient reported outcomes, diagnostic biopsy rate during follow-up, ipsilateral mastectomy rate and translational research. Feasibility To explore interest in and feasibility of the LORD study we conducted a survey among EORTC and BOOG centres. A vast majority of EORTC and BOOG responding centres expressed interest in participation in the LORD study. The proposed study design is endorsed by nearly all centres. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
11. Postoperative brachytherapy for endometrial cancer using a ring applicator.
- Author
-
Vanneste, Ben G.L., Meijnen, Philip, Hammerstein, Chris S.J., Bijker, Nina, van Os, Rob M., Stalpers, Lukas J.A., and Pieters, Bradley R.
- Subjects
- *
TREATMENT of endometrial cancer , *ENDOMETRIAL cancer risk factors , *RADIOISOTOPE brachytherapy , *POSTOPERATIVE period , *HYSTERECTOMY , *OVARIECTOMY - Abstract
Background To evaluate the rate of vaginal, pelvic, and distant failures and acute toxicity after postoperative vaginal vault brachytherapy (VBT) delivered by a ring applicator in women with high intermediate-risk endometrial cancer. Methods and Materials A total of 100 patients were treated with VBT after a total abdominal hysterectomy and bilateral salpingo-oophorectomy for a Stage IA or IB (International Federation of Gynecology and Obstetrics 2009) intermediate-risk endometrial cancer; 26 patients received 30-Gy low-dose-rate, 74 patients received 28-Gy pulsed-dose-rate brachytherapy. Results At a median followup of 37 months (range, 1–107), 6 (6%) patients showed failures. Three patients developed an in-field recurrence in the vaginal vault: 1 was isolate, whereas the other 2 showed simultaneous pelvic and/or distant failure. A fourth patient developed an out-of-field recurrence in the posterior vaginal wall of the proximal half of the vagina, including pelvic and distant failure. Two other patients showed only distant failure. The estimated 3-year actuarial rate of any vaginal recurrence was 2.6% (95% confidence interval, 0–6.3%). The 5-year overall survival was 84%, similar to that in the female Dutch population matched for age and date of diagnosis. The acute side effects were low, consisting mainly of the occurrence of temporary diarrhea (2%). Conclusion Postoperative VBT by a ring applicator results in a low recurrence risk, survival rates comparable with the normal female population, and a very low risk of acute morbidity. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
12. Salvage treatment for local or local-regional recurrence after initial breast conservation treatment with radiation for ductal carcinoma in situ
- Author
-
Solin, Lawrence J., Fourquet, Alain, Vicini, Frank A., Taylor, Marie, Haffty, Bruce, Strom, Eric A., Wai, Elaine, Pierce, Lori J., Marks, Lawrence B., Bartelink, Harry, Campana, Francois, McNeese, Marsha D., Jhingran, Anuja, Olivotto, Ivo A., Bijker, Nina, and Hwang, Wei-Ting
- Subjects
- *
CANCER patients , *SALVAGE therapy , *PATHOLOGY , *ANATOMY - Abstract
Abstract: The present study evaluated the outcome of salvage treatment for women with local or local-regional recurrence after initial breast conservation treatment with radiation for mammographically detected ductal carcinoma in situ (DCIS; intraductal carcinoma) of the breast. The study cohort consisted of 90 women with local only first failure (n =85) or local-regional only first failure (n =5). The histology at the time of recurrence was invasive carcinoma for 53 patients (59%), non-invasive carcinoma for 34 patients (38%), angiosarcoma for one patient (1%), and unknown for two patients (2%). The median follow-up after salvage treatment was 5.5 years (mean=5.8 years; range=0.2–14.2 years). The 10-year rates of overall survival, cause-specific survival, and freedom from distant metastases after salvage treatment were 83%, 95%, and 91%, respectively. Adverse prognostic factors for the development of subsequent distant metastases after salvage treatment were invasive histology of the local recurrence and pathologically positive axillary lymph nodes. These results demonstrate that local and local-regional recurrences can be salvaged with high rates of survival and freedom from distant metastases. Close follow-up after initial breast conservation treatment with radiation is warranted for the early detection of potentially salvageable local and local-regional recurrences. [Copyright &y& Elsevier]
- Published
- 2005
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.